2026 Global: Biothrax (Anthrax Vaccine) Market -Competitive Review (2032) report
Description
The 2026 Global: Biothrax (Anthrax Vaccine) Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for biothrax (anthrax vaccine) market by geography and historical trend. The scope of the report extends to sizing of the biothrax (anthrax vaccine) market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Emergent BioSolutions dominates the BioThrax anthrax vaccine market as the sole FDA-licensed manufacturer of BioThrax (Anthrax Vaccine Adsorbed), producing it at facilities in Michigan and Lansing for pre- and post-exposure prophylaxis against Bacillus anthracis. Altimmune develops next-generation anthrax vaccines, positioning itself as a key innovator alongside Emergent in the competitive landscape. Panacea Biotec Limited contributes through its vaccine portfolio, targeting emerging markets and expanding anthrax countermeasures globally.
Porton Biopharma Limited advances specialized biodefense vaccines, including anthrax candidates, strengthening the market with UK-based production capabilities. Bukit Muria Jaya emerges as a profiled player in regional anthrax vaccine dynamics, particularly in rest-of-world segments. GC Pharma drives pipeline innovations in anthrax therapeutics and vaccines, enhancing global supply chains. Blue Willow Biologics pioneers nasal delivery anthrax vaccines, offering needle-free alternatives to BioThrax. Paratek Pharmaceuticals supports anthrax treatment pipelines with antibiotics, complementing vaccine efforts.
Greffex develops viral vector-based anthrax vaccines, diversifying options beyond Emergent's adsorbed technology. Additional firms like Talecris Biotherapeutics have historically manufactured polyclonal anthrax immune globulins, bolstering Emergent's portfolio through acquisitions and partnerships. These ten companies—Emergent BioSolutions, Altimmune, Panacea Biotec, Porton Biopharma, Bukit Muria Jaya, GC Pharma, Blue Willow Biologics, Paratek Pharmaceuticals, Greffex, and Talecris—collectively shape the BioThrax market, fueled by U.S. government contracts exceeding $900 million and BARDA funding for stockpiles. North America leads demand, with Emergent's expansions enabling 20-25 million doses annually.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for biothrax (anthrax vaccine) market by geography and historical trend. The scope of the report extends to sizing of the biothrax (anthrax vaccine) market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Emergent BioSolutions dominates the BioThrax anthrax vaccine market as the sole FDA-licensed manufacturer of BioThrax (Anthrax Vaccine Adsorbed), producing it at facilities in Michigan and Lansing for pre- and post-exposure prophylaxis against Bacillus anthracis. Altimmune develops next-generation anthrax vaccines, positioning itself as a key innovator alongside Emergent in the competitive landscape. Panacea Biotec Limited contributes through its vaccine portfolio, targeting emerging markets and expanding anthrax countermeasures globally.
Porton Biopharma Limited advances specialized biodefense vaccines, including anthrax candidates, strengthening the market with UK-based production capabilities. Bukit Muria Jaya emerges as a profiled player in regional anthrax vaccine dynamics, particularly in rest-of-world segments. GC Pharma drives pipeline innovations in anthrax therapeutics and vaccines, enhancing global supply chains. Blue Willow Biologics pioneers nasal delivery anthrax vaccines, offering needle-free alternatives to BioThrax. Paratek Pharmaceuticals supports anthrax treatment pipelines with antibiotics, complementing vaccine efforts.
Greffex develops viral vector-based anthrax vaccines, diversifying options beyond Emergent's adsorbed technology. Additional firms like Talecris Biotherapeutics have historically manufactured polyclonal anthrax immune globulins, bolstering Emergent's portfolio through acquisitions and partnerships. These ten companies—Emergent BioSolutions, Altimmune, Panacea Biotec, Porton Biopharma, Bukit Muria Jaya, GC Pharma, Blue Willow Biologics, Paratek Pharmaceuticals, Greffex, and Talecris—collectively shape the BioThrax market, fueled by U.S. government contracts exceeding $900 million and BARDA funding for stockpiles. North America leads demand, with Emergent's expansions enabling 20-25 million doses annually.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
